Modeling promiscuity based on in vitro safety pharmacology profiling data (Q31112194)

28 June 2017

title

Modeling promiscuity based on in vitro safety pharmacology profiling data (English)

1 reference

28 June 2017

1 reference

0 references

Jeremy L Jenkins

0 references

Kamal Azzaoui

1 reference

28 June 2017

Jacques Hamon

1 reference

28 June 2017

Bernard Faller

1 reference

28 June 2017

Steven Whitebread

1 reference

28 June 2017

Edgar Jacoby

1 reference

28 June 2017

Laszlo Urban

1 reference

28 June 2017

publication date

1 June 2007

1 reference

28 June 2017

1 reference

28 June 2017

1 reference

28 June 2017

1 reference

28 June 2017

page(s)

874-880

1 reference

Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications

28 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700036

Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700036

7 January 2021

The "promiscuous drug concept" with applications to Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700036

7 January 2021

"Promiscuous" anticancer drugs that hit multiple targets may thwart resistance.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700036

7 January 2021

Can we rationally design promiscuous drugs?

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700036

7 January 2021

The benefits of the multi-target approach in drug design and discovery

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700036

7 January 2021

Promiscuous drugs compared to selective drugs (promiscuity can be a virtue)

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700036

7 January 2021

Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700036

7 January 2021

QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700036

7 January 2021

Relating protein pharmacology by ligand chemistry

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700036

7 January 2021

G-protein-coupled receptor affinity prediction based on the use of a profiling dataset: QSAR design, synthesis, and experimental validation

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700036

7 January 2021

Analysis of drug-induced effect patterns to link structure and side effects of medicines

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700036

7 January 2021

Development of a virtual screening method for identification of "frequent hitters" in compound libraries

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700036

7 January 2021

Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700036

7 January 2021

A Common Mechanism Underlying Promiscuous Inhibitors from Virtual and High-Throughput Screening

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700036

7 January 2021

Classification of kinase inhibitors using a Bayesian model

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700036

7 January 2021

Enrichment of high-throughput screening data with increasing levels of noise using support vector machines, recursive partitioning, and laplacian-modified naive bayesian classifiers

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700036

7 January 2021

Prediction of biological targets for compounds using multiple-category Bayesian models trained on chemogenomics databases.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700036

7 January 2021

Global mapping of pharmacological space

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700036

7 January 2021

Key aspects of the Novartis compound collection enhancement project for the compilation of a comprehensive chemogenomics drug discovery screening collection

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700036

7 January 2021

Are target-family-privileged substructures truly privileged?

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700036

7 January 2021

The influence of target family and functional activity on the physicochemical properties of pre-clinical compounds

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700036

7 January 2021

Inhibitory effect of carboxylic acid group on hERG binding

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700036

7 January 2021

Can the pharmaceutical industry reduce attrition rates?

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700036

7 January 2021

Comparison of topological descriptors for similarity-based virtual screening using multiple bioactive reference structures

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700036

7 January 2021

The Generation of a Unique Machine Description for Chemical Structures-A Technique Developed at Chemical Abstracts Service

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700036

7 January 2021

Identifiers

DOI

10.1002/CMDC.200700036

1 reference

28 June 2017

1 reference